Dr. Thomas Kakuda, PharmD. is Scientific Director of Clinical Pharmacology at Alios BioPharma, a part of the Janssen Pharmaceutical Companies with Johnson & Johnson. Alios leads the early development efforts within the infectious diseases therapeutic area focusing on developing novel antiviral therapies for hepatitis (e.g. HBV, HCV), respiratory (e.g. influenza, RSV), and other viral infections.
Dr. Kakuda received his Pharm.D. from the University of Pacific, completed a Pharmacy Practice Residency at the National Institutes of Health, and an Infectious Diseases Clinical Pharmacology Fellowship under the mentorship of Dr. Courtney Fletcher, Pharm.D. at the University of Minnesota.
Dr. Kakuda has done extensive work on understanding antiretroviral pharmacology including the development of darunavir and etravirine. Currently he is lead clinical pharmacologist for AL-611 (HCV NS5B inhibitor), AL-3778 (HBV capsid inhibitor), JNJ-64155806 (influenza endonuclease inhibitor), and JNJ-64417184 (RSV non-nucleoside polymerase inhibitor) and is primarily responsible for the development and implementation of clinical pharmacology plans and pharmacokinetic/pharmacodynamic analyses related to the compounds. Dr. Kakuda participates in the International Workshop on Clinical Pharmacology of Antiviral Therapy as an industry liaison.